Alpha-synuclein aggregation involves a bafilomycin A1-sensitive autophagy pathway

Autophagy

Volumn 8, Issue 5, 2012, Pages 754-766

  Klucken, Jochen ^a   Poehler, Anne Maria ^a   Ebrahimi Fakhari, Darius ^b   Schneider, Jacqueline ^a   Nuber, Silke ^c,d   Rockenstein, Edward ^c   Schlötzer Schrehardt, Ursula ^a   Hyman, Bradley T ^b   McLean, Pamela J ^b   Masliah, Eliezer ^c   Winkler, Juergen ^a,c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Alpha synuclein; Dementia with lewy bodies (DLB); Lewy body; Lysosomal degradation; Parkinson disease (PD); Protein aggregation

Indexed keywords

ALPHA SYNUCLEIN; BAFILOMYCIN A1;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOPHAGY; AUTOPHAGY LYSOSOMAL PATHWAY; BRAIN TISSUE; CELL CULTURE; CHAPERONE MEDIATED AUTOPHAGY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROAUTOPHAGY; MALE; MOUSE; NONHUMAN; PROTEIN AGGREGATION; TEMPORAL CORTEX; UPREGULATION;

EID: 84862598619     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.19371     Document Type: Article

References (51)

1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839-40; PMID:9278044; http://dx.doi.org/10.1038/42166
2. Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch MP, et al. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol 2006; 111:101-8; PMID:16482476; http://dx.doi.org/10.1007/s00401-005-0027-7
3. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302:819-22; PMID:14593166; http://dx.doi.org/10.1126/science.1087753
4. Jaeger PA, Wyss-Coray T. All-you-can-eat: autophagy in neurodegeneration and neuroprotection. Mol Neurodegener 2009; 4:16; PMID:19348680; http://dx.doi.org/10.1186/1750-1326-4-16
5. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997; 12:25-31; PMID:9046040
6. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003; 278:25009-13; PMID:12719433; http://dx.doi.org/10.1074/jbc.M300227200
7. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004; 305:1292-5; PMID:15333840; http://dx.doi.org/10.1126/science.1101738
8. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, et al. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of a-synuclein. J Neurosci 2011; 31:14508-20; PMID: 21994367; http://dx.doi.org/10.1523/JNEUROSCI. 1560-11.2011
9. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443:780-6; PMID:17051204; http://dx.doi.org/10.1038/nature05291
10. Dice JF. Chaperone-mediated autophagy. Autophagy 2007; 3:295-9; PMID:17404494
11. Dunn WA, Jr. Studies on the mechanisms of autophagy: maturation of the autophagic vacuole. J Cell Biol 1990; 110:1935-45; PMID:2161853; http://dx.doi.org/10.1083/jcb.110.6.1935
12. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004; 24: 1888-96; PMID:14985429; http://dx.doi.org/10.1523/JNEUROSCI.3809-03.2004
13. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 2009; 4:e5515; PMID:19436756; http://dx.doi.org/10.1371/journal.pone.0005515
14. Yu WH, Dorado B, Figueroa HY, Wang L, Planel E, Cookson MR, et al. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol 2009; 175:736-47; PMID:19628769; http://dx.doi.org/10.2353/ajpath.2009.080928
15. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem 2004; 279:25497-502; PMID:15044495; http://dx.doi.org/10.1074/jbc.M400255200
16. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002; 295:865-8; PMID:11823645; http://dx.doi.org/10.1126/ science.1067389
17. Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman BT. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J 2006; 20:2050-7; PMID:17012257; http://dx.doi.org/10.1096/fj. 05-5422com
18. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287:1265-9; PMID:10678833; http://dx.doi.org/10.1126/science.287.5456.1265
19. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 2009; 29:13578-88; PMID:19864570; http://dx.doi.org/10.1523/JNEUROSCI. 4390-09.2009
20. Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 2005; 280:23727-34; PMID: 15845543; http://dx.doi.org/10.1074/jbc.M503326200
21. Higashi S, Moore DJ, Minegishi M, Kasanuki K, Fujishiro H, Kabuta T, et al. Localization of MAP1-LC3 in vulnerable neurons and Lewy bodies in brains of patients with dementia with Lewy bodies. J Neuropathol Exp Neurol 2011; 70:264-80; PMID:21412173; http://dx.doi.org/10.1097/NEN.0b013e318211c86a
22. Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K. Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease. Neurobiol Dis 2011; 43:690-7; PMID:21684337; http://dx.doi.org/10.1016/j.nbd. 2011.05.022
23. Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 2010; 5:e9313; PMID:20174468; http://dx.doi.org/10.1371/journal.pone.0009313
24. McLean PJ, Kawamata H, Hyman BT. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 2001; 104:901-12; PMID:11440819; http://dx.doi.org/10.1016/S0306-4522(01)00113-0
25. Shacka JJ, Klocke BJ, Roth KA. Autophagy, bafilomycin and cell death: the "a-B-cs" of plecomacrolide-induced neuroprotection. Autophagy 2006; 2:228-30; PMID:16874105
26. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6:304-12; PMID: 17396135; http://dx.doi.org/10.1038/nrd2272
27. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003; 278:44405-11; PMID:12923179; http://dx.doi.org/10.1074/jbc.M308041200
28. Shao E, Forgac M. Involvement of the nonhomologous region of subunit A of the yeast V-ATPase in coupling and in vivo dissociation. J Biol Chem 2004; 279:48663-70; PMID:15355963; http://dx.doi.org/10.1074/jbc.M408278200
29. Dehay B, Bové J, Rodríguez-Muela N, Perier C, Recasens A, Boya P, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010; 30:12535-44; PMID:20844148; http://dx.doi.org/10.1523/JNEUROSCI.1920-10. 2010
30. Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA. Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem 2010; 285:13621-9; PMID:20200163; http://dx.doi.org/10.1074/jbc.M109.074617
31. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol 2010; 67:1464-72; PMID:20697033; http://dx.doi.org/10.1001/ archneurol.2010.198
32. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 2009; 35:385-98; PMID:19505575; http://dx.doi.org/10.1016/j.nbd.2009.05.023
33. Ni-Komatsu L, Tong C, Chen G, Brindzei N, Orlow SJ. Identification of quinolines that inhibit melanogenesis by altering tyrosinase family trafficking. Mol Pharmacol 2008; 74:1576-86; PMID:18801917; http://dx.doi.org/10.1124/mol. 108.050633
34. Rockenstein E, Schwach G, Ingolic E, Adame A, Crews L, Mante M, et al. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J Neurosci Res 2005; 80:247-59; PMID:15765523; http://dx.doi.org/10.1002/jnr.20446
35. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001; 21:9549-60; PMID:11739566
36. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008; 118:777-88; PMID: 18172548
37. Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, et al. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 2006; 76:89-101; PMID:17118264; http://dx.doi.org/10.1016/S0070-2153(06)76003-3
38. Hunke S, Döse S, Schneider E. Vanadate and bafilomycin A1 are potent inhibitors of the ATPase activity of the reconstituted bacterial ATP-binding cassette transporter for maltose (MalFGK2). Biochem Biophys Res Commun 1995; 216:589-94; PMID: 7488152; http://dx.doi.org/10.1006/bbrc.1995.2663
39. Sharom FJ, Yu X, Chu JW, Doige CA. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem J 1995; 308:381-90; PMID:7772017
40. Teplova VV, Tonshin AA, Grigoriev PA, Saris NE, Salkinoja-Salonen MS. Bafilomycin A1 is a potassium ionophore that impairs mitochondrial functions. J Bioenerg Biomembr 2007; 39:321-9; PMID:17917797; http://dx.doi.org/10.1007/ s10863-007-9095-9
41. Shacka JJ, Klocke BJ, Shibata M, Uchiyama Y, Datta G, Schmidt RE, et al. Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons. Mol Pharmacol 2006; 69:1125-36; PMID:16391239; http://dx.doi.org/10.1124/mol. 105.018408
42. González-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquère S, et al. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 2005; 118:3091-102; PMID:15985464; http://dx.doi.org/10.1242/jcs.02447
43. Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol 2007; 3:331-8; PMID: 17486044; http://dx.doi.org/10.1038/nchembio883
44. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007; 282:5641-52; PMID:17182613; http://dx.doi.org/10.1074/jbc.M609532200
45. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113-24; PMID:8909416
46. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 2002; 68:568-78; PMID: 12111846; http://dx.doi.org/10.1002/jnr. 10231
47. Veinbergs I, Van Uden E, Mallory M, Alford M, McGiffert C, DeTeresa R, et al. Role of apolipoprotein E receptors in regulating the differential in vivo neurotrophic effects of apolipoprotein E. Exp Neurol 2001; 170:15-26; PMID:11421580; http://dx.doi.org/10.1006/exnr.2001.7684
48. Kawamata H, McLean PJ, Sharma N, Hyman BT. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. J Neurochem 2001; 77:929-34; PMID:11331421; http://dx.doi.org/10.1046/j.1471-4159. 2001.00301.x
49. Pedraza CE, Bassett DC, McKee MD, Nelea V, Gbureck U, Barralet JE. The importance of particle size and DNA condensation salt for calcium phosphate nanoparticle transfection. Biomaterials 2008; 29:3384-92; PMID:18485472; http://dx.doi.org/10.1016/j.biomaterials.2008.04.043
50. Van Agtmael T, Schlötzer-Schrehardt U, McKie L, Brownstein DG, Lee AW, Cross SH, et al. Dominant mutations of Col4a1 result in basementmembrane defects which lead to anterior segment dysgenesis and glomerulopathy. Hum Mol Genet 2005; 14:3161-8; PMID: 16159887; http://dx.doi.org/10.1093/hmg/ddi348
51. Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, et al. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J 2010; 277:3051-67; PMID:20573181; http://dx.doi.org/10.1111/j.1742-4658.2010.07719.x